Clinical Report: FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A

Overview

The FDA has approved Fayuvi (rebisufligene etisparvovec-hopf), the first gene therapy for Sanfilippo syndrome type A, aimed at treating neurological manifestations in pediatric patients. The therapy demonstrated cognitive improvements in a long-term study compared to untreated patients.

Background

Sanfilippo syndrome type A (MPS IIIA) is an ultrarare lysosomal storage disorder caused by SGSH gene mutations, leading to severe neurological decline in affected children. Prior to this approval, treatment options were limited to symptom management.

Data Highlights

Key Findings

• Fayuvi is the first FDA-approved treatment for Sanfilippo syndrome type A.
• The therapy is a one-time AAV9 gene therapy administered via intravenous infusion.
• Treated patients showed a mean increase of 16 points in cognitive scores compared to a decline in untreated patients.
• 85% of patients experienced elevated liver enzymes as a common adverse reaction.
• Long-term follow-up data indicated cognitive improvements and reductions in cerebrospinal fluid heparan sulfate concentrations.
• Patients require corticosteroid treatment and monitoring for potential adverse effects post-infusion.

Clinical Implications

Clinicians should be aware of the treatment's administration requirements and the need for ongoing monitoring of adverse effects.

Conclusion

Fayuvi's approval marks a milestone in the treatment of Sanfilippo syndrome type A.

Related Resources & Content

1. FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
2. FDA approves gene therapy for MPS IIIA
3. Sanfilippo syndrome: consensus guidelines for clinical care | Orphanet Journal of Rare Diseases
4. United States Department of Health and Human Services — WTAS: FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program
5. MDSpire News — FDA Approves Gene Therapy for Severe Pediatric LAD-I
6. Ophthalmology Management — FDA Grants Fast Track Designation to Sanofi’s Investigational Gene Therapy for GA
7. FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A
8. Sanfilippo syndrome: consensus guidelines for clinical care | Orphanet Journal of Rare Diseases | Springer Nature Link
9. Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)—Ultragenyx Pharmaceutical Inc.